Houlihan Lokey Advises Shore Capital Partners

Houlihan Lokey is pleased to announce that Shore Capital Partners (Shore) has merged Reliant Healthcare (Reliant) and Care Fusion Rx (Care Fusion). The transaction closed on November 20, 2025.

Reliant is an independent infusion therapy company providing home infusion therapy and ambulatory infusion center services to patients with chronic and complex conditions. Reliant is dedicated to delivering high-quality, accessible infusion care that improves patient outcomes and quality of life. Reliant was founded in 2008 and operates 14 ambulatory infusion centers and multiple specialty pharmacies across Louisiana, Texas, and Oklahoma.

Care Fusion is a specialty infusion pharmacy focused on chronic IVIG and specialty biologic therapies. With extensive experience in pharmaceutical and healthcare services, Care Fusion partners with physicians and payors to ensure patients receive consistent access to critical infusion treatments for chronic and rare diseases. Care Fusion is headquartered in Garden Grove, California.

Shore is a private equity investor in middle-market and lower-middle-market companies in the healthcare, food and beverage, business services, industrials, and real estate industries. Shore’s strategy is to support management partners in growing faster with less risk through access to capital, world-class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. Shore is based in Chicago, with offices in Nashville, and has approximately $14 billion of assets under management.

Houlihan Lokey served as a financial advisor to Shore. This transaction further highlights Houlihan Lokey’s leadership in the pharmacy and infusion-related services sector, becoming its 17th announced/closed pharmacy transaction in this space since 2020 and its ninth announced/closed pharmacy transaction since 2024. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the world. In 2024, the group closed 35 transactions and was ranked by LSEG (formerly Refinitiv) as the No. 1 advisor for global healthcare M&A transactions under $1 billion.*

*Excludes accounting firms and brokers.

RELATED: Healthcare, Mergers & Acquisitions